World Courier making multi-million dollar tech investment

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ake1150sbe)
(Image: Getty/ake1150sbe)

Related tags: Logistics, Pharmaceutical companies, Technology, Supply chain, Cell therapy

World Courier has made a multimillion-dollar investment in its supply chain technology to help meet the expanding needs of the pharmaceutical industry.

World Courier opened new offices worldwide in 2018, and unveiled personalized supply chain​ teams to support direct-to-patient​, cell and gene therapy, and clinical trial execution​.

The company began investing in technology solutions and infrastructure in 2015 and has since implemented upgrades in Canada, Portugal, and Japan. Improvements following the most recent investment are set to reach additional markets in 2019.

Sam Herbert, president of World Courier told us, “As technology continues to drive innovation in pharmaceutical care, we must also use it to progress the leading edge of logistics and commercialization platforms. We recognized the opportunity to evolve our solutions even further and provide customers, particularly those introducing highly specialized therapies, greater value.”

This technology “transformation”​ includes real-time temperature and GPS tracking, and will support system integration and enhance order entry functionality for customers.

“In addition, we will now have the ability to further integrate and enable reliable coordination between customers, airlines, and regulatory agencies, all of whom need to be in lock-step as products make their way from manufacturers to patients,” ​said Herbert.

As the pharmaceutical and biomedical industries evolve, our partners expect World Courier to continue to lead the industry in specialty logistics best practices,”​ he said, adding that the company is focusing on proving logistics and efficiency throughout the supply chain by expanding its ability to support partners in additional markets.

Investment details have not been disclosed at this time. 

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more